<DOC>
	<DOCNO>NCT02573376</DOCNO>
	<brief_summary>Approximately one half Americans live Hepatitis C virus ( HCV ) drug user , yet least likely receive HCV treatment . Drug user presume non-adherent therefore deny potentially life-saving therapy . This assumption confirm dispelled prospective pharmacologic adherence study population . Such study would greatly enhance objective , quantitative measure adherence currently exist HCV field . Through work propose application , sixty HIV/HCV co-infected drug user treat direct act antiviral agent ( DAA ) randomize receive directly observe DAA therapy ( DOT ) vs. directly observe therapy ( no-DOT ) . Patients randomize no-DOT wirelessly observe therapy ( WOT ) involve use portable medication dispenser send signal server date time dispenser open . In Aim 1 , DAA concentration compare randomized DOT vs. no-DOT . DAA pharmacokinetics also define account clinical factor like degree hepatic impairment use concomitant recreational antiretroviral drug . The goal quantify adherence population effect variable adherence drug concentration . In Aim 2 , DAA concentration ( plasma , cellular , hair ) link adherence pattern identify use WOT DOT . The goal identify drug concentration biomarker predict adherence population . In Aim 3 , relationship DAA adherence ( measure WOT DOT drug concentration ) rate cure establish . The goal define degree adherence need HCV cure .</brief_summary>
	<brief_title>Antiviral Pharmacology Adherence Drug Users</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Ability give inform consent HIVinfected men woman Chronic HCV infection document quantifiable HCV RNA HCV genotype 1 , 4 , 5 , 6 1870 year age Willingness ability comply study procedure , include DOT , WOT , biweekly clinic visit Considered active drug user HCV provider selfreported drug use within past month Glomerular filtration rate &lt; 30 mL/min/1.73 m2 Receipt prior HCV treatment radiographic , histologic , clinical evidence cirrhosis Decompensated liver disease ( i.e. , ascites , history esophageal variceal bleeding , hepatic encephalopathy ) Medications recommend per SOF/LDV prescribe information ( e.g. , tipranavir Pgp inducer , tenofovir disoproxil fumarate plus cobicistat , rosuvastatin , amiodarone ) Any medical condition opinion investigator make challenge adhere study protocol , unstable heart disease cancer Chronic Hepatitis B virus Infection For female , active pregnancy intent become pregnant For sex , unwillingness use contraception study period On parole impend sentence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Drug Abuse</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>sofosbuvir</keyword>
	<keyword>ledipasvir</keyword>
	<keyword>pharmacology</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>